RE:RE:RE:RE:RE:Shelf - News ReleaseToday's news about the extension of the ATM is in line with results that will only come in 2022. Also, maybe they think it won't be good enough on the efficacy side and that they will need to wait for phase Ib to really see impressive results. Remember results of Trodelvy in dose escalation trial, also, the results of Bicycle given by Wino a few days ago. A couple of partial responses is not likely to push the SP much. Sorry to say that, but I think that it is likely that we will have to wait for the results of phase Ib to see something impressive. This PDC was designed to be used on patients selected for sortilin overexpression. Without that, it is hard to expect spectacular results. Also, they are so late in this trial, that the patients on higher doses are unlikely to have had more than one or two cycles of treatment. As always in drug development, it is a slow process.